(Q36632250)

15 August 2017

1 reference

title

Tolcapone in the management of Parkinson's disease (English)

1 reference

15 August 2017

1 reference

Julie Leegwater-Kim

1

1 reference

15 August 2017

Cheryl Waters

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

16

1 reference

15 August 2017

page(s)

2263-2270

1 reference

Biochemical aspects of Parkinson's disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Other pharmacological treatments for motor complications and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Pathophysiology of motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Tolcapone: a review of its use in the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2263

10.1517/14656566.7.16.2263

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference